Day: February 13, 2025

The CJEU is less claimant-friendly than its AG in use of the anchor defendant mechanism for competition law damages claims. Rules out mini-trials at the jurisdictional stage yet insists on room to contest control. – gavc law – geert van calster – Go Health Pro

by
The CJEU is less claimant-friendly than its AG in use of the anchor defendant mechanism for competition law damages claims. Rules out mini-trials at the jurisdictional stage yet insists on room to contest control. – gavc law – geert van calster – Go Health Pro

The CJEU held earlier this morning in C‑393/23 Athenian Brewery SA, Heineken NV v Macedonian Thrace Brewery SA (no language versions available at the time of posting than Dutch and French). My post on Kokott AG’s Opinion is here. The AG all in all supported a ready acceptance of forum connexitatis in competition law cases – in the … Read more

A Guide to Insurance for Bars, Restaurants, Taverns, and Pubs – Go Health Pro

by
A Guide to Insurance for Bars, Restaurants, Taverns, and Pubs – Go Health Pro

While serving alcohol remains at the heart of your business, it also carries a unique set of liabilities. The right insurance coverage can protect you from financial losses due to accidents, injuries, or lawsuits—and it’s often legally required. Below, we explore several key coverage options and why they matter. Key Coverage Options To protect businesses … Read more

Transgender Rights at a Crossroads in the United States – Go Health Pro

by
Transgender Rights at a Crossroads in the United States – Go Health Pro

In his first month in office, US President Donald Trump has issued a series of sweeping executive orders targeting transgender rights. Thus far, these aim to rigidly define “sex” in federal law, exclude transgender people from military service, ban gender-affirming healthcare for people under the age of 19, restrict support for transgender students in schools, … Read more

Zacks Small Cap Research – ARWR: Multiple Catalysts Ahead in 2025… – Go Health Pro

by

By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Plozasiran Update On January 17, 2025, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for plozasiran for the treatment of familial chylomycronemia syndrome (FCS), with a Prescription Drug User Fee Act … Read more

Spending, Saving And Debt Trends – Forbes Advisor – Go Health Pro

by
Spending, Saving And Debt Trends – Forbes Advisor – Go Health Pro

Editorial Note: We earn a commission from partner links on Forbes Advisor. Commissions do not affect our editors’ opinions or evaluations. The financial landscape in 2025 is shaping up to be anything but predictable. With shifting economic policies, lingering inflation pressures and consumer debt reaching new highs, the question isn’t just whether Americans can stretch … Read more

x